Nolan A Wages, Ph.D.

Public Health Sciences

Nolan A Wages, Ph.D.

Dr. Wages is an Assistant Professor in the Division of Translational Research and Applied Statistics in the Department of Public Health Sciences. As a member of this division, the majority of his research effort is related to cancer research and its applications. Dr. Wages is an active member of the UVA Cancer Center Biostatistics Shared Resource, for which he works with cancer center members on the design and analysis of clinical trials. With funding from a NCI/NIH K25 Mentored Quantitative Research Career Development Award, his current methodological research involves the design and analysis of early-phase clinical trials, with a particular focus on studies of combined immunotherapies.


Assistant Professor
Translational Research & Applied Statistics
Ph.D., Statistics, University of Virginia, 2010

P.O. Box 800717
Tel: 1-434-924-8222
Fax: 1-434-243-5787
West Complex OMS Room 3890


Research Interests:

  • Design and analysis of early-phase clinical trials in oncology.


Teaching Responsibilities:

  • Introduction to Statistics session, Foundations of Medicine, Fall 2014
  • Biostatistics Short Course to Rad/Onc Residents and Heme/Onc Fellows, Spring 2014
  • PHS 7000 - Biostatistics I, J-Term 2014


Other Information:


  1. Conaway MR, Wages NA. Phase I trials and dose-finding. (2015). In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis, to appear.
  2. Rosenberger LH, Guidry CA, Davis JP, Hranjec T, Johnston VK, Wages NA, Watson CM, Sawyer RG. (2015). Reducing accidental dislodgements of the percutaneous endoscopic gastrostomy: a prospective investigational device trial of the "SafetyBreak." Surg Innov, to appear.
  3. Hirakawa A, Wages NA, Sato H, Matsui S. (2015). A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. Stat Med; [epub ahead of print].
  4. Wages NA, Read PW, Petroni GR. (2015). A phase I/II adaptive design for heterogeneous groups with application to a stereotactic radiation therapy trial. Pharm Stat; [epub ahead pf print].
  5. Romano AM, Wages NA, Smolkin M, La Fortune K, Atkins K, Dillon PM. (2015). Low-grade tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification. Breast Dis; [epub ahead of print].
  6. Wages NA, Tait C. (2015). Seamless phase I/II adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat; [epub ahead of print].
  7. Wages NA, Conaway MR, Slingluff CL, Williams ME, Portell CA, Hwu P, Petroni GR. (2015). Recent developments in the implementation of novel designs for early-phase combination studies. Ann Oncol; 26: 1036-1037.
  8. Wages NA, Slingluff CL, Petroni GR. (2015). A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials; 41: 172-79.
  9. Wages NA. (2015). Comments on 'Competing designs for drug combination phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar. Stat Med; 34: 18-22.
  10. Wages NA, Conaway MR, O'Quigley J. (2014). Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Stat Med; 33: 2156-2158.
  11. Wages NA, Conaway MR. (2014). Phase I/II adaptive design for drug combination oncology trials. Stat Med; 33: 1990-2003.
  12. Showalter TN, Wages NA, Ohri N. (2014). Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: New clinical trial designs should be considered. Cancer Biol Ther; 15: 361-364.
  13. Wages NA, O'Quigley J, Conaway MR. (2014). Phase I design for completely or partially ordered treatment schedules. Stat Med; 33: 569-579.
  14. Wages NA, Conaway MR, O'Quigley J. (2013). Performance of two-stage continual reassessment method relative to an optimal benchmark. Clin Trials; 10: 862-875.
  15. Wages NA, Varhegyi N. (2013). pocrm: An R package for phase I trials of combinations of agents. Comput Methods Programs Biomed; 112: 211-218.
  16. Wages NA, Conaway MR. (2013). Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat; 12: 217-224.
  17. Wages NA, Conaway MR, O’Quigley J. (2013). Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med; 32: 131–141.
  18. Wages NA, Liu L, O’Quigley J, Johnson B. (2012). Obtaining the optimal dose in alcohol dependence studiesFront Psychiatry; 3:100.
  19. Wages NA, Conaway MR, O’Quigley J. (2011). Continual reassessment method for partial ordering. Biometrics; 67: 1555–1563.
  20. Wages NA, Conaway MR, O’Quigley J. (2011). Dose-finding design for multi-drug combinations. Clin Trials; 8: 380–389.
  21. O'Quigley J, Wages NA. (2008). Dose escalation guided by graded toxicities. Wiley Encyclopedia of Clin Trials; 1-6